Tscan Therapeutics Inc (TCRX) Live Share Price, Invest From India

Tscan Therapeutics Inc Stock Performance

as on May 23, 2026 at 2:15 pm IST

Day's Low
Day's High
$1.00
Day's Price Range
$1.08
$1.06
5.66%
Downside
1.89%
Upside
52 Week's Low
52 Week's High
$0.88
52-Week Price Range
$2.57
$1.06
16.75%
Downside
142.45%
Upside

Tscan Therapeutics Inc share price movements today

Previous Close: $1.02
Open: $1.03
Volume: 1.4M
Day's Low - High: $1.00 - $1.08
52 Week Low - High: $0.88 - $2.57

Tscan Therapeutics Inc Historical Returns

1 Month Return: -18.4 %
3 Month Return: + 0.99 %
1 Year Return: -29.17 %
3 Year Return: -68.03 %
5 Year Return: 0 %

Tscan Therapeutics Inc Stock Fundamentals & Key Indicators

Check Tscan Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$66.0M

EPS (TTM)

-0.8425

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-123.8M

Revenue (TTM)

9.1M

Profit Margin

0.00%

Return On Equity TTM

-80.95%

Tscan Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Tscan Therapeutics Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Tscan Therapeutics Inc	BUY	$66.0M	NA	NA	0.00%
Alnylam Pharmaceuticals Inc	BUY	$39.9B	114.56%	75.18	12.55%
Vertex Pharmaceuticals Inc	BUY	$109.2B	103.13%	25.58	35.51%
Regeneron Pharmaceuticals Inc	BUY	$68.1B	26.81%	15.87	29.65%

Stock Returns calculator for Tscan Therapeutics Inc Stock including INR - Dollar returns

The Tscan Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Tscan Therapeutics Inc investment value today

Current value as on today

₹82,666

Returns

-₹17,334

(-17.33%)

Returns from Tscan Therapeutics Inc Stock

-₹26,389 (-26.39%)

Dollar Impact

₹9,055 (+9.05%)

Analyst Recommendation on Tscan Therapeutics Inc Stock

Based on 12 analysts

BUY

91.67%

Buy

8.33%

Hold

0.00%

Sell

Based on 12 analysts, 91.67% of analysts recommend a 'BUY' rating for Tscan Therapeutics Inc. Average target price of $6

Tscan Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Tscan Therapeutics Inc.

What analysts predicted

82.33%UPSIDE

Target Price

Current Price

$1.06

Analyzed by

12 Analysts

Target

$6.00

Tscan Therapeutics Inc target price $6, a slight upside of 82.33% compared to current price of $1.06. According to 12 analysts rating.

Indian Investors' Interest in Tscan Therapeutics Inc Stock

Search interest for Tscan Therapeutics Inc Stock has increased by 67% in the last 30 days, reflecting an upward trend in search activity.

Time period: April 23, 2026 to May 23, 2026

Change:67% versus previous 30 day period

Tscan Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Revenue	7	0	0	1	0	2	3	2	2	0
Gross Profit	5	0	0	1	0	2	3	2	2	0
Operating Income	-21	-31	-34	-32	-36	-36	-38	-37	-23	-29
EBITDA	-17	-27	-29	-27	-34	-32	-35	-34	-21	-28
Interest Expense	0	0	0	0	0	0	0	0	0	0
Depreciation	1	1	1	1	0	0	0	0	0	0
Income Before Tax	-19	-30	-31	-29	-35	-34	-36	-35	-22	-28
Income Tax Expense	-1	-1	-1	-	1	-	-	-	-	-
Net Income	-19	-30	-31	-29	-35	-34	-36	-35	-22	-28
Net Profit Margin	-271.99%	-5325.44%	-5906.90%	-2849.09%	-5384.81%	-1571.95%	-1201.30%	-1422.14%	-895.09%	-2919.14%

Tscan Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	1	10	13	21	2	10
Gross Profit	-9	-19	10	13	21	2	7
Operating Income	-14	-26	-48	-66	-93	-134	-135
EBITDA	-13	-25	-45	-59	-80	-119	-132
Interest Expense	-	-	0	1	3	3	2
Depreciation	0	1	3	5	5	4	2
Income Before Tax	-13	-26	-48	-66	-89	-127	-129
Income Tax Expense	0	0	3	0	5	-	-
Net Income	-13	-26	-48	-66	-89	-127	-129
Net Profit Margin	0.00%	-2408.02%	-479.49%	-489.26%	-423.86%	-4527.66%	-1256.81%

Tscan Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Net Income	-30	-31	-29	-35	-34	-36	-35	-22	-28
Operating Cash Flow	-29	-26	-27	-27	-37	-33	-32	-32	-24
Investing Cash Flow	36	-33	-82	27	13	48	32	14	0
Financing Cash Flow	0	161	1	45	0	0	-	0	-
Change in Cash	7	101	-109	45	-24	15	0	-17	-24

Tscan Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-26	-48	-66	-89	-127	-129
Operating Cash Flow	-3	-48	-66	-61	-110	-135
Investing Cash Flow	-4	-9	-4	-60	-52	109
Financing Cash Flow	0	189	29	135	208	0
Change in Cash	-6	131	-41	13	45	-26

Global Institutional Holdings in Tscan Therapeutics Inc

Funds	Holdings
Aberdeen Group PLC	1.53%
UBS Group AG	0.71%
DC Funds, LP	1.05%
DC Funds, LP	1.05%
Marshall Wace Asset Management Ltd	0.56%

See all

Insights on Tscan Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 3 years, TScan Therapeutics, Inc. Common Stock has experienced a drawdown of -60.3%, however Alnylam Pharmaceuticals, Inc. Common Stock resisted the overall trend and outperformed by 46.1%
NO EFFECT
Against Peers
In the last 1 year, Regeneron Pharmaceuticals, Inc. Common Stock has given 9.2% return, outperforming this stock by 35.3%
NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 2.56M → 982.0K (in $), with an average decrease of 61.8% per quarter
NEGATIVE IMPACT
Price Dip
In the last 1 month, TCRX stock has moved down by -15.0%
NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, -22.97M → -28.66M (in $), with an average decrease of 24.8% per quarter

About Tscan Therapeutics Inc

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Organisation	Tscan Therapeutics Inc
Headquarters	830 Winter Street, Waltham, MA, United States, 02451
Industry	Biotechnology
CEO	Dr. Gavin MacBeath Ph.D.
E-voting on shares	Click here to vote

Key Management of Tscan Therapeutics Inc

Name	Title
Dr. Gavin MacBeath Ph.D.	CEO & Director
Mr. Jason A. Amello CPA	CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer
Mr. Tomasz Kula Ph.D.	Co-Founder & Member of Advisory Board
Ms. Ann Hargraves	Chief Human Resources Officer
Dr. Shrikanta Chattopadhyay M.D.	Senior VP & Head of Translational Medicine
Mr. Ray Lockard M.B.A.	Chief Manufacturing & Quality Officer
Mr. Jim Murray	Chief Development Operations Officer
Dr. Chrystal U. Louis M.D., M.P.H.	Chief Medical Officer
Dr. Stephen J. Elledge Ph.D.	Co-Founder & Chairman of Scientific Advisory Board
Dr. Zoran Zdraveski J.D., Ph.D.	Chief Legal & Strategy Officer and Company Secretary

FAQs

What is Tscan Therapeutics Inc share price today?

Tscan Therapeutics Inc share price today is $1.06 as on May 23, 2026 at 8:45 am IST at the close of the market. Tscan Therapeutics Inc share today touched a day high of $1.08 and a low of $1.

What is the 52 week high and 52 week low for Tscan Therapeutics Inc share?

Tscan Therapeutics Inc share touched a 52 week high of $2.57 on October 16, 2025 and a 52 week low of $0.88 on December 19, 2025. Tscan Therapeutics Inc stock price today i.e. May 23, 2026 at 8:45 am IST is closed at $1.06,which is 58.75% down from its 52 week high and 20.13% up from its 52 week low.

What is Tscan Therapeutics Inc's market capitalisation today?

Tscan Therapeutics Inc market capitalisation is $0.00T as on May 23, 2026 at 8:45 am IST.

How to invest in Tscan Therapeutics Inc Stock (TCRX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Tscan Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Tscan Therapeutics Inc Shares that will get you 1.4151 shares as per Tscan Therapeutics Inc share price of $1.06 per share as on May 23, 2026 at 8:45 am IST.

What is the minimum amount required to buy Tscan Therapeutics Inc Stock (TCRX) from India?

Indian investors can start investing in Tscan Therapeutics Inc (TCRX) shares with as little as ₹95.68 or $1 (as of May 23, 2026 at 5:59 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹956.80 in Tscan Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on May 23, 2026 at 5:59 pm IST). Based on Tscan Therapeutics Inc share’s latest price of $1.06 as on May 23, 2026 at 8:45 am IST, you will get 9.4340 shares of Tscan Therapeutics Inc. Learn more about fractional shares .